KAT6A was first identified as a fusion partner of CREBBP in the context of AML, with the fusion (KAT6A-CREBBP) functioning as a transcriptional co-activator that promotes leukemogenesis [94,95,96]. The gene discussed is CREBBP; the disease is acute myeloid leukemia.